Abstracts tagged "inflammation and nephritis"

Abstract Number: 571 • 2013 ACR/ARHP Annual Meeting
Protective Effect Of Inducible Adeno-Associated Virus Mediated IL-2 Gene Therapy On Tissue Damages In Lupus-Prone Mice
Masayuki Mizui¹, Tomohiro Koga², Linda Lieberman³, Jessica Beltran³, Mark C. Johnson⁴, José C. Crispin², Roland Tisch⁴ and George C. Tsokos⁵, ¹Division of Rheumatology, Department of Medicine,, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: IL-2 plays critical roles not only in immune responses but also in peripheral tolerance. Impairment of IL-2 production has been linked to the development…
Abstract Number: 554 • 2013 ACR/ARHP Annual Meeting
Identification Of Stage Specific Genes Associated With Lupus Nephritis and Response To Remission induction In NZB/W Mice
Ramalingam Bethunaickan¹, Celine C. Berthier², Hong-dong Li³, Weijia Zhang⁴, Yuanfang Guan⁵, Matthias Kretzler⁶ and Anne Davidson⁷, ¹Autoimmunity, Feinstein Institute for Medical Research, Manhasset, NY, ²Nephrology, University of Michigan, Ann Arbor, MI, ³Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, ⁴Mount Sinai School of Medicine, New York, NY, ⁵Department of Computational Medicine and Bioinformatics, Department of Medicine, University of Michigan, Ann Arbor, MI, ⁶Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, ⁷Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Our goal was to use transcriptome analysis to elucidate the molecular mechanisms involved in the immunopathogenesis of renal inflammation during the onset, remission and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].